{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T17:48:20Z","timestamp":1793814500618,"version":"4.6.1"},"reference-count":25,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.annonc.2025.03.012","type":"journal-article","created":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T12:14:12Z","timestamp":1743250452000},"page":"775-785","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":45,"title":["Subcutaneous versus intravenous pembrolizumab, in combination with chemotherapy, for treatment of metastatic non-small-cell lung cancer: the phase III 3475A-D77 trial"],"prefix":"10.1016","volume":"36","author":[{"given":"E.","family":"Felip","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.I.","family":"Rojas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Schenker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.M.","family":"Kowalski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.A.","family":"Casarini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Cs\u00f6szi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.A.N.","family":"\u015eendur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Martins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Calles Blanco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.-C.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.A.L.","family":"Ramirez Fallas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7724-0481","authenticated-orcid":false,"given":"H.","family":"Yoshioka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Nair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Lala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Eiras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8188-2505","authenticated-orcid":false,"given":"T.","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.annonc.2025.03.012_bib1","doi-asserted-by":"crossref","first-page":"4396","DOI":"10.1007\/s12325-024-02985-9","article-title":"Differences between intravenous and subcutaneous modes of administration in oncology from the patient, healthcare provider, and healthcare system perspectives: a systematic review","volume":"41","author":"Aguiar-Ibanez","year":"2024","journal-title":"Adv Ther"},{"key":"10.1016\/j.annonc.2025.03.012_bib2","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.ejca.2021.03.047","article-title":"Preference for the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer (PHranceSCa): a randomised, open-label phase II study","volume":"152","author":"O\u2019Shaughnessy","year":"2021","journal-title":"Eur J Cancer"},{"issue":"4","key":"10.1016\/j.annonc.2025.03.012_bib3","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1093\/annonc\/mdw685","article-title":"Preference for subcutaneous or intravenous administration of rituximab among patients with untreated CD20+ diffuse large B-cell lymphoma or follicular lymphoma: results from a prospective, randomized, open-label, crossover study (PrefMab)","volume":"28","author":"Rummel","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2025.03.012_bib4","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.2147\/PPA.S453920","article-title":"Description of feelings, perception, and experience before and after switching from IV daratumumab to the SC form: a mixed-method, cross-sectional survey in multiple myeloma patients in Europe","volume":"18","author":"Magarotto","year":"2024","journal-title":"Patient Prefer Adherence"},{"issue":"10","key":"10.1016\/j.annonc.2025.03.012_bib5","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/S1470-2045(13)70383-8","article-title":"Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study","volume":"14","author":"Pivot","year":"2013","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.annonc.2025.03.012_bib6","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s41669-022-00361-3","article-title":"A systematic review of time and resource use costs of subcutaneous versus intravenous administration of oncology biologics in a hospital setting","volume":"7","author":"McCloskey","year":"2023","journal-title":"Pharmacoecon Open"},{"issue":"3","key":"10.1016\/j.annonc.2025.03.012_bib7","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1002\/cam4.573","article-title":"A time and motion study of subcutaneous versus intravenous trastuzumab in patients with HER2-positive early breast cancer","volume":"5","author":"De Cock","year":"2016","journal-title":"Cancer Med"},{"issue":"12","key":"10.1016\/j.annonc.2025.03.012_bib8","first-page":"804","article-title":"Real-world assessment of patient care and practice efficiency with the introduction of subcutaneous rituximab","volume":"35","author":"Drill","year":"2021","journal-title":"Oncology (Williston Park)"},{"issue":"12","key":"10.1016\/j.annonc.2025.03.012_bib9","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1007\/s12094-017-1684-4","article-title":"Cost minimization analysis of treatment with intravenous or subcutaneous trastuzumab in patients with HER2-positive breast cancer in Spain","volume":"19","author":"Lopez-Vivanco","year":"2017","journal-title":"Clin Transl Oncol"},{"issue":"3","key":"10.1016\/j.annonc.2025.03.012_bib10","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1200\/OP.24.00021","article-title":"Subcutaneous vs intravenous trastuzumab\/pertuzumab: a time and motion substudy of a phase II trial of adjuvant trastuzumab\/pertuzumab for stage I HER2+ breast cancer (ADEPT trial)","volume":"21","author":"Waks","year":"2025","journal-title":"JCO Oncol Pract"},{"key":"10.1016\/j.annonc.2025.03.012_bib11","doi-asserted-by":"crossref","unstructured":"Coetzee C, Khanyile R, Cohen G, et al. Pharmacokinetics, safety, and tolerability of pembrolizumab with berahyaluronidase alfa administered subcutaneously Q3W in participants with advanced melanoma. Poster presented at the AACR Annual Meeting 2025. 2025; Chicago, IL, USA (poster number is CT035).","DOI":"10.1158\/1538-7445.AM2025-CT035"},{"key":"10.1016\/j.annonc.2025.03.012_bib12","doi-asserted-by":"crossref","unstructured":"Reig Torras O, Cohen G, Cho BC, et al. Bioavailability of MK-3475A (pembrolizumab with berahyaluronidase alfa; \u201csubcutaneous pembrolizumab\u201d) in participants with advanced or metastatic solid tumors. Poster presented at the AACR Annual Meeting 2025. 2025; Chicago, IL, USA (poster number is CT036).","DOI":"10.1158\/1538-7445.AM2025-CT036"},{"issue":"2","key":"10.1016\/j.annonc.2025.03.012_bib13","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.annonc.2025.03.012_bib14","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1198\/sbr.2010.10010","article-title":"Multiple and repeated testing of primary, coprimary, and secondary hypotheses","volume":"3","author":"Maurer","year":"2011","journal-title":"Stat Biopharm Res"},{"issue":"2","key":"10.1016\/j.annonc.2025.03.012_bib15","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/sim.4780040211","article-title":"Comparative analysis of two rates","volume":"4","author":"Miettinen","year":"1985","journal-title":"Stat Med"},{"key":"10.1016\/j.annonc.2025.03.012_bib16","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ejca.2020.02.016","article-title":"A six-weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation","volume":"131","author":"Lala","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.annonc.2025.03.012_bib17","unstructured":"Food & Drug Administration. Bioavailability and Bioequivalence Studies Submitted in NDAs or INDs - General Considerations. 2014. Available at https:\/\/www.fda.gov\/media\/88254\/download. Accessed February 19, 2025."},{"key":"10.1016\/j.annonc.2025.03.012_bib18","unstructured":"European Medicines Agency. Guideline on the Pharmacokinetic and Clinical Evaluation of Modified Release Dosage Forms. European Medicines Agency; 2014. Available at https:\/\/www.fda.gov\/media\/88254\/download. Accessed February 19, 2025."},{"issue":"1","key":"10.1016\/j.annonc.2025.03.012_bib19","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.annonc.2024.09.002","article-title":"Subcutaneous versus intravenous nivolumab for renal cell carcinoma","volume":"36","author":"Albiges","year":"2025","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.annonc.2025.03.012_bib20","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.annonc.2023.05.009","volume":"34","author":"Burotto","year":"2023","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.annonc.2025.03.012_bib21","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1186\/s40425-019-0663-4","article-title":"Immunogenicity of pembrolizumab in patients with advanced tumors","volume":"7","author":"van Vugt","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"22","key":"10.1016\/j.annonc.2025.03.012_bib22","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.annonc.2025.03.012_bib23","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1056\/NEJMoa1810865","article-title":"Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer","volume":"379","author":"Paz-Ares","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.annonc.2025.03.012_bib24","doi-asserted-by":"crossref","unstructured":"De Cock E, Oskar S, Lourdudoss C, et al. A multi-country time & motion study of subcutaneous vs intravenous pembrolizumab plus chemotherapy in metastatic non-small cell lung cancer. Poster presented at the European Lung Cancer Congress 2025. 2025; Paris, France (poster number is 33P).","DOI":"10.1016\/S1556-0864(25)00228-X"},{"issue":"3","key":"10.1016\/j.annonc.2025.03.012_bib25","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"}],"updated-by":[{"DOI":"10.1016\/j.annonc.2026.02.002","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T00:00:00Z","timestamp":1775520000000}}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753425001231?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753425001231?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T19:49:14Z","timestamp":1787428154000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753425001231"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":25,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S0923753425001231"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2025.03.012","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Subcutaneous versus intravenous pembrolizumab, in combination with chemotherapy, for treatment of metastatic non-small-cell lung cancer: the phase III 3475A-D77 trial","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2025.03.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Merck & Co., Inc., Rahway, NJ, USA and its affiliates and The Author(s). Published by Elsevier Ltd. on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}]}}